Global Idiopathic Pulmonary Fibrosis Market

According to latest analysis by Gen Consulting Company, the global idiopathic pulmonary fibrosis market is poised to grow by USD 2.0 billion during 2022-2028, progressing at a CAGR of 7.5% during the forecast period.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global idiopathic pulmonary fibrosis market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the idiopathic pulmonary fibrosis industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the drug type, action mode, end user, and region. The global market for idiopathic pulmonary fibrosis can be segmented by drug type: Nintedanib, Pirfenidone, others. The Nintedanib segment held the largest share of the global idiopathic pulmonary fibrosis market in 2021 and is anticipated to hold its share during the forecast period. Idiopathic pulmonary fibrosis market is further segmented by action mode: antifibrotic agent, tyrosine kinase inhibitor, other. Globally, the tyrosine kinase inhibitor segment made up the largest share of the idiopathic pulmonary fibrosis market. Based on end user, the idiopathic pulmonary fibrosis market is segmented into: hospital and clinic, others. The hospital and clinic segment was the largest contributor to the global idiopathic pulmonary fibrosis market in 2021. On the basis of region, the idiopathic pulmonary fibrosis market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America is estimated to account for the largest share of the global idiopathic pulmonary fibrosis market.

Market Segmentation
By drug type: Nintedanib, Pirfenidone, others
By action mode: antifibrotic agent, tyrosine kinase inhibitor, other
By end user: hospital and clinic, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The global idiopathic pulmonary fibrosis market report offers detailed information on several market vendors, including Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, FibroGen Inc., Horizon Therapeutics Public Limited Company, Jubilant Pharma Limited, MediciNova Inc., Merck & Co. Inc., Roche Holding AG, United Therapeutics Corporation, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global idiopathic pulmonary fibrosis market.
– To classify and forecast the global idiopathic pulmonary fibrosis market based on drug type, action mode, end user, region.
– To identify drivers and challenges for the global idiopathic pulmonary fibrosis market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global idiopathic pulmonary fibrosis market.
– To identify and analyze the profile of leading players operating in the global idiopathic pulmonary fibrosis market.

Why Choose This Report
– Gain a reliable outlook of the global idiopathic pulmonary fibrosis market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.

Global Idiopathic Pulmonary Fibrosis Market

Interested in this report? Get your FREE sample now!
Global Idiopathic Pulmonary Fibrosis Market - Report Scope
REPORT ATTRIBUTE

DETAILS

Base Year

2021

Forecast Year

2022-2028

CAGR (2022-2028)

7.47%

Pages

87

Key Players

Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, FibroGen Inc., Horizon Therapeutics Public Limited Company, Jubilant Pharma Limited, MediciNova Inc., Merck & Co. Inc., Roche Holding AG, United Therapeutics Corporation

Related Reports
China Skin Care and Treatment Market 2023

The skin care and treatment market in China, in terms of revenue, is expected to grow by 9.9 percent annually through 2029, according to the latest estimates. Skin care is essential for maintaining skin health and preventing skin conditions. It helps to protect the skin from environmental factors, such as…

READ MORE
China Skin-related Beauty Market 2023

According to the latest research, the skin-related beauty market in China is estimated to increase at the rate of 10.1% each year in the period from 2023 to 2029. Skin-related beauty refers to the products and treatments aimed at improving the health, appearance, and overall condition of the skin. It…

READ MORE
Global Suction Catheter Market

Global suction catheter market by product (closed suction catheter, open suction catheter), by region (Asia-Pacific, Europe, North America, Middle East and Africa (MEA), South America), outlook & forecast, 2023-2029

READ MORE

$2,750.00

Want to customize this report?
The present report possesses the flexibility to be tailored to your specific needs. Our team of analysts and industry experts will collaborate directly with you to gain a comprehensive understanding of your requirements.
Scroll to Top

Download Free Sample - Global Idiopathic Pulmonary Fibrosis Market

Please fill out our form and we will get back to you.